MUC1 which is over-expressed and aberrantly glycosylated in most epithelial tumor cells is one of the most promising targets for cancer immunotherapy.However MUC1 is weakly immunogenic,since it is a self-antigen.Therefore,the vaccines based on MUC1 need to combine with extra adjuvants for strong immune response.Here we used a new strategy for developing antitumor vaccine,which is totally synthetic and adjuvant-free,containing self-assembling domain Q11 and B-cell epitopes(see Figure 1)[1].This kind of vaccines could effectively stimulate immune system of mice and elicit high levels of antibody.This non-covalent vaccine hold the promise for antitumor vaccine.